1. Artivion to release Q4 and full year 2024 results on Feb 24, 2025. 2. Teleconference scheduled on the same day to discuss financial results. 3. Company focuses on cardiac and vascular surgery solutions for aortic diseases. 4. Artivion's products marketed in over 100 countries, broadening potential market impact.
Upcoming earnings reports often drive stock interest. AORT's focus on aortic diseases may attract investors.
Quarterly earnings key for assessing AORT growth, influencing investor decisions.
The impact will likely be felt around the earnings release date.
ATLANTA, Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.
To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13749878.
The live webcast and replay can be accessed on the Investors section of the Artivion website at www.artivion.com and by selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investors section of the Artivion website.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Artivion
Lance A. Berry
Executive Vice President & Chief Financial Officer
Phone: 770-419-3355
Gilmartin Group LLC
Brian Johnston / Laine Morgan
Phone: 332-895-3222
[email protected]
SOURCE Artivion, Inc.